摘要
目的:对原发性肝癌患者经皮肝动脉化疗栓塞(TACE)术前、术后采用RECIST1.0和mRECIST测量比较,为原发性肝癌患者TACE术后提供更准确的疗效评价方法。方法:70例确诊为原发性肝癌患者至少做过3次化疗栓塞术,并于TACE术前1周内、术后1月、3月内行CT四期扫描,至少两名放射科医生参与阅片,根据RECIST1.0和mRECIST评价标准评估治疗的缓解程度。两种方法评价缓解率的比较采用χ2检验。结果:采用RECIST1.0标准评价的完全缓解(CR)为0例、部分缓解(PR)为9例、疾病稳定(SD)为38例、疾病进展(PD)为23例,缓解率为12.86%;采用mRECIST标准评价原发性肝癌TACE术后CR为12例、PR为15例、SD为22例、PD为21例,缓解率为38.57%,经χ2检验,P<0.05,二者有显著性统计学差异。结论:采用mRECIST标准对原发性肝癌TACE作疗效评价,强调治疗后动脉期强化的存活肿瘤测量,对判断后续治疗有一定的指导意义。
Objective： CT was used to compare using the response evaluation cirteria in solid tumor 1.0（RECIST1.0） and modified RECIST（mRECIST） in evaluation the treatment effect of TACE for patients with HCC, so as to choose a more optimal cirteria for evaluating the treatment effect. Methods： Seventy patients diagnosed as HCC had at least 3 chemoembolization procedures, and at 1 week before the procedure; 1 month; 3 months after the procedures had CT or MR examinations respectively. At least two radiologists according to RECIST1.0 and mRECIST criterion to assess the result of TACE therapy. The response rate of the two criterion was evaluated with χ^2test. Results： Use RECIST1.0 to evaluate the therapeutic effect of TACE： CR was 0, PR was 9, SD was 38, PD was 23, response rate was 12.86%. If use mRECIST for evaluation： CR was12, PR was 15, SD was 22, PD was 21, response rate was 38.57%（χ^2test, P〈0.05）, There was significant differences between the two criterion. Conclusion： To use mRECIST criteria in evaluating the response rate of TACE treatment for HCC, emphasis is put on measuring the enhanced viable tumor in the arterial phase by enhanced CT, it can play a decisive role for subsequent treatment planning.
出处
《中国临床医学影像杂志》
CAS
2014年第9期623-626,共4页
Journal of China Clinic Medical Imaging
关键词
肝肿瘤
化学栓塞
治疗性
体层摄影术
螺旋计算机
Liver neoplasms
Chemoembolization
therapeutic
Tomography
spiral computed
